| Patent application number | Description | Published |
|---|
| 20080200385 | Annexin for Cancer Risk Assessment - A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal. | 08-21-2008 |
| 20090061461 | Phosphorylated or Non-Phosphorylated MPR as Diagnostic Marker or Therapeutic Target - A method of diagnosing diseases associated with aberrant biological phenotypes including contacting a sample to be tested with at least one isoform of membrane associated progesterone receptor component 1 (mPR) as a diagnostic marker, and determining or estimating the degree of phosphorylation of the membrane associated progresterone receptor component 1 (mPR). | 03-05-2009 |
| 20090170889 | USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVENTION OR TREATMENT OF NEUROLOGICALLY-ASSOCIATED DISORDERS - The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine-nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy. The demonstrated inhibition of the MPTP appears to constitute a novel principle applicable to all pathological conditions which have underlying excitotoxic/mitochondrial mechanisms, like: amyotrophic lateral sclerosis, Alzheimer's disease, depression, epilepsy, multiple sclerosis, pain, Parkinson's disease, schizophrenia, traumatic brain and spinal chord injury, stroke and other ischemic conditions in the brain. | 07-02-2009 |
| 20090286273 | USE OF NEUREGULIN-BETA AS AN INDICATOR AND/OR TARGET - The invention relates, inter alia, to the use of neuregulin-β as a target in a screening method for active compounds, in particular for exerting an influence on changes in calcium concentration which are mediated by glutamate receptors. | 11-19-2009 |
| 20100129834 | AUTOIMMUNE REGULATION OF PROSTATE CANCER BY ANNEXIN A3 - The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3 (ANXA3) and/or autoantibodies against ANXA3 with a specific reagent. The method allows differentiation between benign, premalignant and malignant conditions. Further, the method has a prognostic relevance. | 05-27-2010 |
| 20100233160 | Monoclonal Anti-Annexin A3 Antibodies for the Detection of Prostate Carcinoma - The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3, particularly of extracellular annexin A3 with highly specific antibodies, particularly with monoclonal antibodies. The present invention further refers to a test reagent comprising such antibodies. | 09-16-2010 |
| 20100247688 | PIRENZEPINE AND DERIVATIVES THEREOF AS ANTI-AMYLOID AGENTS - The present invention relates to a compound that is capable of inhibiting the formation of β-amyloid plaques, of reducing and/or retarding the increase the β-amyloid plaque load in the brain of an animal, particularly a mammal, but especially a human. In particular, the invention relates to compounds of formula (I) and to metabolites thereof. | 09-30-2010 |
| 20100267051 | ANNEXIN FOR CANCER RISK ASSESSMENT - A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal. | 10-21-2010 |
| 20110098234 | BREAST CANCER PROTEINS - The present invention relates to a pooling method for performing proteomics with human samples, preferably derived from microdissected human samples, wherein the samples are grouped into two or more pools and each pool reveals at least one protein that is differentially manifest between these pools but common to a member of a given pool. Besides, the invention refers to proteins whose abundances are upregulated in cancer cells, especially in breast cancer cells, preferably in breast cancer cells that are positive or negative towards hormone binding receptors. | 04-28-2011 |
| 20110143366 | PROTEIN BIOMARKERS FOR IN VITRO TESTING OF DEVELOPMENTAL TOXICITY AND ENBRYOTOXICITY OF CHEMICAL SUBSTANCES - Presently, the toxicological assessment of chemicals is mainly performed in vivo using a variety of animal species and in addition taking into account human clinical, biochemical, pathological and morphological data. Over the past years it became increasingly clear that some substances are particularly harmful for children and thus there is a focus on the special vulnerability of the developing human brain. Meanwhile there is a recommendation to test substances with a known neurotoxic or teratogenic (in particular a neuroteratogenic) risk additionally for embryotoxicity. Moreover the US Environmental Protection Agency (EPA) requires embryotoxicity tests for pesticides. Further tests are required if substances shall be used as medicaments (S7A Safety Pharmacology Studies for Human Pharmaceuticals, Guidelines of the International Conference on Harmonization, ICH, 2001). | 06-16-2011 |
